Medication

Amylyx Pharmaceuticals Appoints Bernhardt Zeiher, MD, FCCP, FACP, to its Board of Directors

Retrieved on: 
Thursday, March 14, 2024
Biotechnology, Pharmaceutical, Health, Neurology, Medication, Astellas Pharma, Pfizer, ALS, Science, Wolfram syndrome, University, FACP, AMX0035, Research, Doctor of Philosophy, MD, Biology, Critical care, Palsy, Drug development, FCCP, Amylyx Pharmaceuticals, Pharmacovigilance, Eli Lilly and Company, CMO, Wolfram, Biotechnology Innovation Organization, Neurodegenerative disease, Medicine, Pharmaceutical industry

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced the addition of Bernhardt G. Zeiher, MD, FCCP, FACP, to its Board of Directors (“Board”).

Key Points: 
  • Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced the addition of Bernhardt G. Zeiher, MD, FCCP, FACP, to its Board of Directors (“Board”).
  • Most recently, he served as Chief Medical Officer (“CMO”) of Astellas Pharma, where he led early- and late-stage drug development, medical and regulatory affairs, pharmacovigilance, and quality assurance.
  • “Dr.
  • Zeiher brings to the Board his distinguished drug development background in overseeing the approval of 15 medicines, and his first-hand experience as a physician.

docs24 Announces Formation of Global Advisory Board

Retrieved on: 
Thursday, March 14, 2024
Health, Technology, Software, Clinical Trials, Research, Science, Pharmaceutical, Medication, ChromeOS, Advisory board, Pharmaceutical industry

docs24, a leading document management solutions provider for the clinical research sector, is proud to announce the establishment of its Global Advisory Board.

Key Points: 
  • docs24, a leading document management solutions provider for the clinical research sector, is proud to announce the establishment of its Global Advisory Board.
  • docs24 welcomes to the Board Dr Jeff Thomis of Thomis Consulting, global information technology professional Elizabeth Theophille, and Devana Solutions Founder & President, Barry Lake.
  • The formation of the Advisory Board reflects docs24's commitment to excellence and its dedication to fostering collaborations with thought leaders in the sector.
  • With Board members from around the globe, the diverse backgrounds and perspectives that make up the Global Advisory Board reflect the multidisciplinary nature of the life sciences industry.

Sensorion Reports Full-Year 2023 Financial Results and Business Update

Retrieved on: 
Thursday, March 14, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, Bioreactor, Malignancy, Cell, Chemistry, Patient, Orphan, Good manufacturing practice, Health care, CMC, G&A, Molecular biology, Quality of life, European Medicines Agency, Science, Clinical trial, Cisplatin, Therapy, Hertz, Neoplasm, CIO, Congress, Huber loss, Partnership, Ageing, EMA, Hearing loss, GMP, Cochlea, Biochemistry, Safety, Language, Perilymph, G7, Medication, Control, AAV, PTA, IHC, Pasteur Institute, CDMO, Communication, Genetics, Research, KOL, Ear, POC, FDA, Ototoxicity, GJB2, ABR, CTA, ANSM, Audiogram, Platinum, Investment company, Congenital hearing loss, Pathology, Presbycusis, Hearing, Pharmaceutical industry

Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, today reports full-year 2023 financial results and business update.

Key Points: 
  • Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, today reports full-year 2023 financial results and business update.
  • Nawal Ouzren, Chief Executive Officer of Sensorion, said: “Over the past months, Sensorion has successfully achieved all the major milestones on its roadmap.
  • In the first half of 2023, Sensorion achieved a major development milestone by completing the preclinical package, and successfully producing the GMP dual AAV SENS-501 clinical batches at 200L scale.
  • On April 6, 2023, Sensorion announced the candidate selection for GJB2-GT during its gene therapy focused R&D Day.

Connie Announces Expansion of Flagship Medication Safety Tool to Protect Connecticut Residents

Retrieved on: 
Wednesday, March 13, 2024
Data Management, Health, Technology, Practice Management, Health Technology, Software, Pharmaceutical, Polypharmacy, Organization, Health information exchange, Risk, Patient, Pharming, Reconciliation (United States Congress), Hospital, Death, Medication, Immunodeficiency, HIE, MHA

Connie , the State of Connecticut’s nonprofit health information exchange (HIE), marked another year of successfully leveraging a nation-leading innovative medication safety tool.

Key Points: 
  • Connie , the State of Connecticut’s nonprofit health information exchange (HIE), marked another year of successfully leveraging a nation-leading innovative medication safety tool.
  • Utilized by healthcare providers across the state who collectively serve more than 4.5 million patients, the tool’s demonstrated impact has paved the way for expansion of the program.
  • The Medication Management tool — developed by Connie based on the work of the Medication Reconciliation and Polypharmacy Work Group, per Connecticut General Assembly’s Special Act 18-6 — empowers healthcare providers not only by storing medication data and advancing deduplication processes, but also dispatching critical information to the point of care.
  • “Developing the tool to realize the vision of the Best Possible Medication History workgroup into a functioning Medication Management tool exemplifies what’s so great about Connie,” said Searls.

Alnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive Disease

Retrieved on: 
Wednesday, March 13, 2024
Science, Other Science, Research, Pharmaceutical, General Health, Health, Genetics, Other Health, Diagnosis, Alnylam Pharmaceuticals, Dizziness, Medication, Learning, Weakness, Genetic testing, Disease, TTR, Risk, Human, Patient, Common, Knowledge, Constipation, Diarrhea, Child, Amyloidosis, MBA, MPH, Heart, RNA interference, Carpal tunnel syndrome, Therapy, Multimedia, Family, Pharmaceutical industry

“Family history is considered one of the most important risk factors for health problems.

Key Points: 
  • “Family history is considered one of the most important risk factors for health problems.
  • “It took seeing nine doctors over seven years for me to finally receive a diagnosis of hATTR amyloidosis,” said Christine, a Family Health History Road Trip participant who is living with hATTR amyloidosis.
  • If I had, I could have potentially been diagnosed and started on a disease management plan much earlier.”
    With an inherited disease like hATTR amyloidosis that progresses rapidly, early diagnosis is crucial.
  • A genetic test can determine whether a person carries one of the more than 120 variants in the TTR gene associated with hATTR amyloidosis.

Mirum Pharmaceuticals’ LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis

Retrieved on: 
Wednesday, March 13, 2024
Health, FDA, Infectious Diseases, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Growth, Medication, Alagille syndrome, Disease, Patient, Shanda, Sleep, ALGS, Cholestatic pruritus, Quality of life, Life, Cholestasis, Multimedia, Itch, Collection, Family, Food, Pharmaceutical industry

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that the U.S. Food and Drug Administration (FDA) has approved LIVMARLI® (maralixibat) oral solution for the treatment of cholestatic pruritus in patients five years of age and older with progressive familial intrahepatic cholestasis (PFIC).

Key Points: 
  • Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that the U.S. Food and Drug Administration (FDA) has approved LIVMARLI® (maralixibat) oral solution for the treatment of cholestatic pruritus in patients five years of age and older with progressive familial intrahepatic cholestasis (PFIC).
  • View the full release here: https://www.businesswire.com/news/home/20240313135184/en/
    LIVMARLI® (maralixibat) oral solution is now available for prescribing in the US for cholestatic pruritus in patients with PFIC.
  • “LIVMARLI has the potential to have a transformational impact for patients with cholestatic pruritus associated with PFIC, and importantly, offers an option for those patients with the rarest of subtypes,” said Chris Peetz, chief executive officer at Mirum.
  • We are hopeful that LIVMARLI will have a measurable impact for patients, potentially offering a new normal and relief from the sleepless nights and disruption to their lives caused by cholestatic pruritus.”

Longboard Pharmaceuticals Reports Full Year 2023 Financial Results and Provides Corporate Updates

Retrieved on: 
Tuesday, March 12, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Other Health, Medication, Seizure, Standard of care, LGS, DEE, DS, Safety, SAD, FDA, DSM-IV codes, Pharmaceutical industry

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported full year 2023 financial results.

Key Points: 
  • Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported full year 2023 financial results.
  • “I am extremely proud of what our team has accomplished starting with the immense effort that went into the PACIFIC Study in participants with DEEs.
  • We appreciate the tremendous support from our existing and new shareholders who play an integral part in the continued success of Longboard.
  • Of note, results were on top of current standard of care; participants were typically on 3-4 other anti-seizure medications.

Venatorx Pharmaceuticals Expands Senior Leadership Team

Retrieved on: 
Tuesday, March 12, 2024
Research, Infectious Diseases, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Financial management, Quality control, Medication, Virginia University, Information technology, Goldman Sachs, CFO, Business, Shire (pharmaceutical company), State university system, Patient, Accounting, Strategic planning, NDA, CMC, IPO, Senior, HBV, MBA, Ernst & Young, Mylan, Chemistry, Investment, Therapy, Lehigh University, West Virginia University, CPA, Management

"These additions to our senior leadership team are critical to ensure we are prepared for our NDA resubmission and are strategically positioned for continued success."

Key Points: 
  • "These additions to our senior leadership team are critical to ensure we are prepared for our NDA resubmission and are strategically positioned for continued success."
  • He joined Venatorx from Aimmune/Nestle Health Science where he was a Senior Vice President and Head of Technical Operations.
  • Before this, he was the Senior Vice President of Technical Operations with Paratek Pharmaceuticals and over the years has worked at Eagle Pharmaceuticals, Shire with aaiPharma, Elan Pharmaceuticals, Sandoz, and Mylan Pharmaceuticals.
  • Previously, he was Vice President, Technical Assessment and Senior Director for Business Development at Shire Pharmaceuticals to build the product pipeline and support Shire's strategic venture arm through investments.

Digital Printing Packaging Market worth $46.2 billion by 2029 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Friday, April 5, 2024
Variable, Smurfit Kappa, Growth, Medication, Digital, Health, Printing, Trust, Risk, ACME, Perception, Research, CCL Industries, Sonoco, Constantia Flexibles, Investment, WestRock, Elanders, Paper, Marketing, VDP, Medicine, Amcor, 3D printing

One of the key drivers of the rapid growth of inkjet printing in the packaging industry is its ability to handle short print runs and variable data printing efficiently.

Key Points: 
  • One of the key drivers of the rapid growth of inkjet printing in the packaging industry is its ability to handle short print runs and variable data printing efficiently.
  • Variable data printing (VDP) provides packaging manufacturers with greater flexibility and efficiency in managing inventory and production.
  • The Asia Pacific region is witnessing significant investments in infrastructure and technological advancements, further driving the growth of the digital printing packaging market.
  • Governments and industry players are increasingly investing in modern printing facilities, digital printing equipment, and research and development initiatives to enhance printing capabilities, improve print quality, and reduce production costs, thereby boosting the adoption of digital printing technology in the packaging industry.

Digital Printing Packaging Market worth $46.2 billion by 2029 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Friday, April 5, 2024
Variable, Smurfit Kappa, Growth, Medication, Digital, Health, Printing, Trust, Risk, ACME, Perception, Research, CCL Industries, Sonoco, Constantia Flexibles, Investment, WestRock, Elanders, Paper, Marketing, VDP, Medicine, Amcor, 3D printing

One of the key drivers of the rapid growth of inkjet printing in the packaging industry is its ability to handle short print runs and variable data printing efficiently.

Key Points: 
  • One of the key drivers of the rapid growth of inkjet printing in the packaging industry is its ability to handle short print runs and variable data printing efficiently.
  • Variable data printing (VDP) provides packaging manufacturers with greater flexibility and efficiency in managing inventory and production.
  • The Asia Pacific region is witnessing significant investments in infrastructure and technological advancements, further driving the growth of the digital printing packaging market.
  • Governments and industry players are increasingly investing in modern printing facilities, digital printing equipment, and research and development initiatives to enhance printing capabilities, improve print quality, and reduce production costs, thereby boosting the adoption of digital printing technology in the packaging industry.